title: Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
abstract: The aim of the present study was to evaluate the impact of a multiple dose regimen of a liposomal formulation of meglumine antimoniate (LMA) on the pharmacokinetics of antimony in the bone marrow of dogs with visceral leishmaniasis and on the ability of LMA to eliminate parasites from this tissue. Dogs naturally infected with Leishmania chagasi received 4 intravenous doses of either LMA (6.5 mg antimony/kg body weight, N = 9), or empty liposomes (at the same lipid dose as LMA, N = 9) at 4-day intervals. A third group of animals was untreated (N = 8). Before each administration and at different times after treatment, bone marrow was obtained and analyzed for antimony level (LMA group) by electrothermal atomic absorption spectrometry, and for the presence of Leishmania parasites (all groups). There was a significant increase of antimony concentration from 0.76 microg/kg wet organ (4 days after the first dose) to 2.07 microg/kg (4 days after the fourth dose) and a half-life of 4 days for antimony elimination from the bone marrow. Treatment with LMA significantly reduced the number of dogs positive for parasites (with at least one amastigote per 1000 host cells) compared to controls (positive dogs 30 days after treatment: 0 of 9 in the LMA group, 3 of 9 in the group treated with empty liposomes and 3 of 8 in the untreated group). However, complete elimination of parasites was not achieved. In conclusion, the present study showed that multiple dose treatment with LMA was effective in improving antimony levels in the bone marrow of dogs with visceral leishmaniasis and in reducing the number of positive animals, even though it was not sufficient to achieve complete elimination of parasites.
authors.affiliation: Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, 30123 Belo Horizonte, MG, Brazil.
authors.forename: D A
authors.initials: DA
authors.lastname: Schettini
authors.forename: A P
authors.initials: AP
authors.lastname: Costa Val
authors.forename: L F
authors.initials: LF
authors.lastname: Souza
authors.forename: C
authors.initials: C
authors.lastname: Demicheli
authors.forename: O G F
authors.initials: OG
authors.lastname: Rocha
authors.forename: M N
authors.initials: MN
authors.lastname: Melo
authors.forename: M S M
authors.initials: MS
authors.lastname: Michalick
authors.forename: F
authors.initials: F
authors.lastname: Frézard
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001853:Bone Marrow / Q000737:chemistry* / Q000469:parasitology; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D008081:Liposomes; D008297:Male; D008536:Meglumine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013054:Spectrophotometry, Atomic
chemical_list: D000981:Antiprotozoal Agents; D008081:Liposomes; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate